SCHEMBL1004280

SCHEMBL1004280

CN1CCC(c2ccccc2C(O)(C(=O)O)c2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 5/20 0.54
RBP4 P02753 7/20 0.48
ALDH1A1 P00352 1/20 0.43
HTR6 P50406 1/20 0.42
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30128750 0.85 ATM (0.50) CHRM3RBP4ALDH1A1
SCHEMBL17294705 0.85 ATM (0.50) CHRM3RBP4ALDH1A1
SCHEMBL9792947 0.83 CHRM3 (0.52) CHRM3RBP4ALDH1A1
SCHEMBL6926259 0.78 GRM2 (0.49) CHRM3RBP4HTR6
SCHEMBL6425438 0.78 CYP3A4 (0.43)
Benzylic Acid SCHEMBL28790412 0.76 CHRM3 (0.54) CHRM3ALDH1A1CYP2C9
SCHEMBL4404703 0.75 CYP2C9 (0.40) CHRM3RBP4CYP2C9
SCHEMBL15935180 0.75 RBP4 (0.44) RBP4HTR6
SCHEMBL5160638 0.74 IKBKB (0.41) HTR6CYP2C9
SCHEMBL5712869 0.74 CHRM2 (0.53) CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082203-A1 PROCESS TO DIAGNOSE OR TREAT BRAIN INJURY BANYAN BIOMARKERS, INC. 2011-04-07 US claimed
EP-2245466-A2 PROCESS TO DIAGNOSE OR TREAT BRAIN INJURY Banyan Biomarkers, Inc. (US) 2010-11-03 EP claimed
WO-2009100131-A2 PROCESS TO DIAGNOSE OR TREAT BRAIN INJURY BANYAN BIOMARKERS, INC. (US) 2009-08-13 WO claimed
WO-2024107948-A1 BIOMARKER PANEL FOR BRAIN SPECIFIC ABNORMAL NEUROLOGICAL CONDITIONS USING BIOFLUID SAMPLES GRYPHON BIO, INC. (US) 2024-05-23 WO disclosed
US-10041959-B2 Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury BANYAN BIOMARKERS, INC. (US) 2018-08-07 US disclosed
EP-3355059-A2 BIOMARKER ASSAY OF NEUROLOGICAL CONDITION Banyan Biomarkers, Inc. (US) 2018-08-01 EP disclosed
EP-2478360-B1 AUTOANTIBODY MARKERS FOR DIAGNOSIS OF TRAUMATIC BRAIN INJURY BANYAN BIOMARKERS INC (US) 2018-06-27 EP disclosed
US-20170315136-A9 BIOMARKER ASSAY OF NEUROLOGICAL CONDITION BANYAN BIOMARKERS, INC. (US) 2017-11-02 US disclosed
US-20170242041-A1 MICRO-RNA, AUTOANTIBODY AND PROTEIN MARKERS FOR DIAGNOSIS OF NEURONAL INJURY BANYAN BIOMARKERS, INC. (US) 2017-08-24 US disclosed
EP-3115785-A2 PROCESS TO DIAGNOSE OR TREAT BRAIN INJURY Banyan Biomarkers, Inc. (US) 2017-01-11 EP disclosed
US-20150268252-A1 BIOMARKER ASSAY OF NEUROLOGICAL CONDITION BANYAN BIOMARKERS, INC. 2015-09-24 US disclosed
US-20110097392-A1 ANTIBODY BOUND SYNTHETIC VESICLE CONTAINING MOLECULES FOR DELIVER TO CENTRAL AND PERIPHERAL NERVOUS SYSTEM CELLS BANYAN BIOMARKERS, INC 2011-04-28 US disclosed
US-20110082203-A1 PROCESS TO DIAGNOSE OR TREAT BRAIN INJURY BANYAN BIOMARKERS, INC. 2011-04-07 US disclosed
WO-2011032155-A2 MICRO-RNA, AUTOANTIBODY AND PROTEIN MARKERS FOR DIAGNOSIS OF NEURONAL INJURY BANYAN BIOMARKERS, INC. (US) 2011-03-17 WO disclosed
WO-2011011334-A2 SYNERGISTIC BIOMARKER ASSAY OF NEUROLGICAL CONDITION USING S-100β BANYAN BIOMARKERS, INC. (US) 2011-01-27 WO disclosed
EP-2274011-A2 AN ANTIBODY BOUND SYNTHETIC VESICLE CONTAINING ACTIVE AGENT MOLECULES Banyan Biomarkers, Inc. (US) 2011-01-19 EP disclosed
WO-2010148391-A2 BIOMARKER ASSAY OF NEUROLOGICAL CONDITION BANYAN BIOMARKERS, INC. (US) 2010-12-23 WO disclosed
EP-2245466-A2 PROCESS TO DIAGNOSE OR TREAT BRAIN INJURY Banyan Biomarkers, Inc. (US) 2010-11-03 EP disclosed
WO-2009129476-A2 AN ANTIBODY BOUND SYNTHETIC VESICLE CONTAINING ACTIVE AGENT MOLECULES BANYAN BIOMARKERS, INC. (US) 2009-10-22 WO disclosed
WO-2009100131-A2 PROCESS TO DIAGNOSE OR TREAT BRAIN INJURY BANYAN BIOMARKERS, INC. (US) 2009-08-13 WO disclosed